Therapeutics and Clinical Risk Management is a pioneering journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of medication safety, pharmacology, and clinical risk management through rigorous research and comprehensive reviews. With an impact factor that demonstrates its significance within various disciplines, this Open Access journal has been instrumental since its inception in 2006, promoting the dissemination of knowledge to a global audience without barriers. With its reach spanning categories such as Pharmacology, Medicine, and Chemical Health and Safety, it champions innovative practices and risk assessment methodologies. The journal is recognized in the Q2 quartile for multiple related categories and excels in rank within its field, highlighting its influential contributions to safety and therapeutic practices. By prioritizing the sharing of impactful research, Therapeutics and Clinical Risk Management serves as an indispensable resource for researchers, professionals, and students aiming to enhance clinical outcomes and mitigate risks in therapeutic paradigms.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

International Journal of Occupational Safety and Ergonomics, ISSN 1080-3548, is a leading multidisciplinary journal published by TAYLOR & FRANCIS LTD with a dedicated focus on advancing research and practices in occupational safety and ergonomics. Since its inception in 1995, this journal has provided a platform for the dissemination of innovative studies that address critical issues in public health, environmental and occupational health, and safety research. Recognized for its rigorous peer-review process, the journal holds a respectable position in the Q2 quartile rankings across multiple categories as of 2023, reflecting its impact and relevance within the academic community. It ranks 24th out of 109 in Safety Research, 198th out of 665 in Public Health, and 66th out of 207 in Safety, Risk, Reliability and Quality, showcasing its influence in these essential fields. The journal's broad scope aims to bridge gaps between research and application, ensuring that findings contribute to effective safety practices in various industries. While not an Open Access journal, the International Journal of Occupational Safety and Ergonomics remains an invaluable resource for researchers, professionals, and students seeking to stay informed about the evolving landscape of occupational safety. Its headquarters are located in Abingdon, England, serving as a conduit for scholarly communication in this vital area of study.

The Journal of Health and Safety at Work, published by the Iranian Occupational Health Association, is a vital resource for researchers, professionals, and students engaged in the fields of occupational health, safety, and environmental management. With an ISSN of 2251-807X and E-ISSN 2383-2088, this Open Access journal has been dedicated to disseminating knowledge since 2012, ensuring that critical research is accessible to a global audience. The journal’s scope encompasses a diverse range of topics including human factors and ergonomics, safety research, and public health, with a focus on enhancing workplace safety and environmental standards. Although currently positioned in the Q4 category across various disciplines within safety and health research, the journal offers a unique platform for emerging studies and innovative practices, making it a significant contributor to the discourse in these fields. The journal's commitment to open access aligns with the growing trend of transparent scholarship, thus facilitating the sharing of vital insights to improve workplace health and safety outcomes. Researchers aiming to publish groundbreaking studies in this pivotal area will find the Journal of Health and Safety at Work an indispensable avenue for advancing knowledge and fostering professional collaboration.

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.